Summary of Precipio (PRPO) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Quarterly Revenue: Exceeded $7 million for the first time, marking a 22% year-over-year increase from $5.7 million in Q2 2025.

Pathology Revenue: Approximately $6.1 million, a slight increase from $6 million in Q1 2026.

Product Revenue: Approximately $900,000, up 35% from $660,000 in Q1 2026, and 21% above the previous record of $750,000 in Q4 2025.

Adjusted EBITDA: Positive at approximately $400,000, a $600,000 improvement from negative $200,000 in Q1 2026.

Operating Cash Flow: Generated approximately $700,000, with total cash increasing to over $3 million, up $0.5 million from the previous quarter.

2Strategic Updates and Business Highlights

Flywheel Model: Precipio's strategy focuses on integrating its laboratory and product divisions to address real-world diagnostic challenges, enhancing both revenue streams.

AML Diagnostic Solutions: The company highlighted its rapid AML diagnostic, which provides results within one day, significantly improving patient care.

Commercial Pipeline: Added 10 new distributor representatives and identified over 25 new qualified customers, indicating growth potential in the product division.

Marketing Initiatives: Plans to enhance marketing collaborations and clinical studies to promote their solutions.

3Forward Guidance and Outlook

Revenue Growth: Expect continued growth in revenue, particularly in the product division, with a focus on converting the commercial pipeline into active accounts.

Operating Leverage: Anticipate further improvements in adjusted EBITDA and cash generation as revenue increases.

Execution Focus: Emphasis on building and converting the product pipeline, innovating new products, and enhancing shareholder value.

4Bad News, Challenges, or Points of Concern

Market Dynamics: The company acknowledged the challenges of working with large distributors, each with unique operational structures, which can slow down sales ramp-up.

Trading Activity: There was unusual trading activity with 800,000 shares traded over two days, which raised questions about market transparency and investor interest.

Historical Revenue Fluctuations: Previous quarters showed relatively flat revenue, leading to investor concerns about the pace of growth.

5Notable Q&A Insights

Trading Activity Inquiry: CEO Ilan Danieli expressed uncertainty regarding the spike in trading volume, attributing it partially to increased investor relations efforts and potential algorithmic trading influences.

Investor Engagement: The company is actively participating in investment conferences to enhance visibility and attract investor interest. Overall, Precipio's Q2 2026 results reflect a strong operational performance with significant revenue growth and improved profitability metrics, while also highlighting ongoing challenges in market dynamics and trading transparency. The company is optimistic about its strategic initiatives and future growth potential.